 D68 |
 |
Other coagulation defects  |
| |
| Excludes1 |
abnormal coagulation profile NOS (R79.1)
|
| Excludes2 |
coagulation defects complicating abortion or ectopic or molar pregnancy (O00-O07, O08.1)
coagulation defects complicating pregnancy, childbirth and the puerperium (O45.0, O46.0, O67.0, O72.3)
|
|
| |
| D68.0 |
|
Von Willebrand disease |
| |
| Excludes1 |
capillary fragility (hereditary) (D69.8)
factor VIII deficiency NOS (D66)
factor VIII deficiency with functional defect (D66)
|
|
| |
 D68.00 |
|
Von Willebrand disease, unspecified |
| | |
| D68.01 |
|
Von Willebrand disease, type 1 |
| |
| Partial quantitative deficiency of von Willebrand factor | | Type 1C von Willebrand disease |
|
| | |
| D68.02 |
|
Von Willebrand disease, type 2 |
| |
| Qualitative defects of von Willebrand factor |
|
| |
| D68.020 |
|
Von Willebrand disease, type 2A |
| |
| Qualitative defects of von Willebrand factor with decreased platelet adhesion and selective deficiency of high-molecular-weight multimers |
|
| | |
| D68.021 |
|
Von Willebrand disease, type 2B |
| |
| Qualitative defects of von Willebrand factor with high-molecular-weight von Willebrand factor loss | | Qualitative defects of von Willebrand factor with hyper-adhesive forms | | Qualitative defects of von Willebrand factor with increased affinity for platelet glycoprotein lb |
|
| | |
| D68.022 |
|
Von Willebrand disease, type 2M |
| |
| Qualitative defects of von Willebrand factor with defective platelet adhesion with a normal size distribution of von Willebrand factor multimers |
|
| | |
| D68.023 |
|
Von Willebrand disease, type 2N |
| |
| Qualitative defects of von Willebrand factor with defective von Willebrand factor to factor VIII binding | | Qualitative defects of von Willebrand factor with markedly decreased affinity for factor VIII |
|
| | |
| D68.029 |
|
Von Willebrand disease, type 2, unspecified |
| |
| Qualitative defect in von Willebrand factor function, with no further subtyping |
|
| | | |
| D68.03 |
|
Von Willebrand disease, type 3 |
| |
| (Near) complete absence of von Willebrand factor | | Total quantitative deficiency of von Willebrand factor |
|
| | |
| D68.04 |
|
Acquired von Willebrand disease |
| |
| Acquired von Willebrand syndrome |
|
| | |
| D68.09 |
|
Other von Willebrand disease |
| |
| Platelet-type von Willebrand disease | | Pseudo-von Willebrand disease |
| CodeAlso |
, if applicable, qualitative platelet defects (D69.1)
|
|
| |
| |
| D68.1 |
|
Hereditary factor XI deficiency |
| |
| Hemophilia C | | Plasma thromboplastin antecedent [PTA] deficiency | | Rosenthal's disease |
|
|
| |
| D68.2 |
|
Hereditary deficiency of other clotting factors |
| |
| AC globulin deficiency | | Congenital afibrinogenemia | | Deficiency of factor I [fibrinogen] | | Deficiency of factor II [prothrombin] | | Deficiency of factor V [labile] | | Deficiency of factor VII [stable] | | Deficiency of factor X [Stuart-Prower] | | Deficiency of factor XII [Hageman] | | Deficiency of factor XIII [fibrin stabilizing] | | Dysfibrinogenemia (congenital) | | Hypoproconvertinemia | | Owren's disease | | Proaccelerin deficiency |
|
|
| |
| D68.3 |
|
Hemorrhagic disorder due to circulating anticoagulants |
| |
| D68.31 |
|
Hemorrhagic disorder due to intrinsic circulating anticoagulants, antibodies, or inhibitors |
| |
| D68.311 |
|
Acquired hemophilia |
| |
| Autoimmune hemophilia | | Autoimmune inhibitors to clotting factors | | Secondary hemophilia |
|
| | |
| D68.312 |
|
Antiphospholipid antibody with hemorrhagic disorder |
| |
| Lupus anticoagulant (LAC) with hemorrhagic disorder | | Systemic lupus erythematosus [SLE] inhibitor with hemorrhagic disorder |
| Excludes1 |
antiphospholipid antibody, finding without diagnosis (R76.0)
antiphospholipid antibody syndrome (D68.61)
antiphospholipid antibody with hypercoagulable state (D68.61)
lupus anticoagulant (LAC) finding without diagnosis (R76.0)
lupus anticoagulant (LAC) with hypercoagulable state (D68.62)
systemic lupus erythematosus [SLE] inhibitor finding without diagnosis (R76.0)
systemic lupus erythematosus [SLE] inhibitor with hypercoagulable state (D68.62)
|
|
| | |
| D68.318 |
|
Other hemorrhagic disorder due to intrinsic circulating anticoagulants, antibodies, or inhibitors |
| |
| Antithromboplastinemia | | Antithromboplastinogenemia | | Hemorrhagic disorder due to intrinsic increase in antithrombin | | Hemorrhagic disorder due to intrinsic increase in anti-VIIIa | | Hemorrhagic disorder due to intrinsic increase in anti-IXa | | Hemorrhagic disorder due to intrinsic increase in anti-XIa |
|
| | | |
| D68.32 |
|
Hemorrhagic disorder due to extrinsic circulating anticoagulants |
| |
| Drug-induced hemorrhagic disorder | | Hemorrhagic disorder due to increase in anti-IIa | | Hemorrhagic disorder due to increase in anti-Xa | | Hyperheparinemia |
| UseAdditionalCode |
code for adverse effect, if applicable, to identify drug (T45.515, T45.525)
|
|
| |
| |
| D68.4 |
|
Acquired coagulation factor deficiency |
| |
| Deficiency of coagulation factor due to liver disease | | Deficiency of coagulation factor due to vitamin K deficiency |
| Excludes1 |
vitamin K deficiency of newborn (P53)
|
|
|
| |
| D68.5 |
|
Primary thrombophilia |
| |
| Primary hypercoagulable states |
| Excludes1 |
antiphospholipid syndrome (D68.61)
lupus anticoagulant (D68.62)
secondary activated protein C resistance (D68.69)
secondary antiphospholipid antibody syndrome (D68.69)
secondary lupus anticoagulant with hypercoagulable state (D68.69)
secondary systemic lupus erythematosus [SLE] inhibitor with hypercoagulable state (D68.69)
systemic lupus erythematosus [SLE] inhibitor finding without diagnosis (R76.0)
systemic lupus erythematosus [SLE] inhibitor with hemorrhagic disorder (D68.312)
thrombotic thrombocytopenic purpura (M31.19)
|
|
| |
| D68.51 |
|
Activated protein C resistance |
| |
|
| | |
| D68.52 |
|
Prothrombin gene mutation |
| | |
| D68.59 |
|
Other primary thrombophilia |
| |
| Antithrombin III deficiency | | Hypercoagulable state NOS | | Primary hypercoagulable state NEC | | Primary thrombophilia NEC | | Protein C deficiency | | Protein S deficiency | | Thrombophilia NOS |
|
| |
| |
| D68.6 |
|
Other thrombophilia |
| |
| Other hypercoagulable states |
| Excludes1 |
diffuse or disseminated intravascular coagulation [DIC] (D65)
heparin induced thrombocytopenia (HIT) (D75.82-)
hyperhomocysteinemia (E72.11)
|
|
| |
| D68.61 |
|
Antiphospholipid syndrome |
| |
| Anticardiolipin syndrome | | Antiphospholipid antibody syndrome |
| Excludes1 |
anti-phospholipid antibody, finding without diagnosis (R76.0)
anti-phospholipid antibody with hemorrhagic disorder (D68.312)
lupus anticoagulant syndrome (D68.62)
|
|
| | |
| D68.62 |
|
Lupus anticoagulant syndrome |
| |
| Lupus anticoagulant | | Presence of systemic lupus erythematosus [SLE] inhibitor |
| Excludes1 |
anticardiolipin syndrome (D68.61)
antiphospholipid syndrome (D68.61)
lupus anticoagulant (LAC) finding without diagnosis (R76.0)
lupus anticoagulant (LAC) with hemorrhagic disorder (D68.312)
|
|
| | |
| D68.69 |
|
Other thrombophilia |
| |
| COVID-19 associated hypercoagulability | | Hypercoagulable states NEC | | Secondary hypercoagulable state NOS |
| CodeAlso |
, if applicable, associated condition
|
|
| |
| |
| D68.8 |
|
Other specified coagulation defects |
| |
| COVID-19 associated coagulopathy |
| CodeAlso |
, if applicable, associated condition
|
| Excludes1 |
hemorrhagic disease of newborn (P53)
|
|
|
| |
| D68.9 |
|
Coagulation defect, unspecified |
|